XML 53 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
Share-Based Compensation (Tables)
6 Months Ended
Jun. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Summary of Equity Awards Authorized and Available for Future Grant
A summary of the equity awards authorized and available for future grants under the 2018 Plan is as follows:
Available for future grants at December 31, 2017

Newly authorized shares
3,800,000

Granted
(925
)
Cancellation and forfeitures

Plan termination

Available for future grants at June 30, 2018
3,799,075

A summary of the equity awards authorized and available for future grants under the 2015 Plan is as follows:
Available for future grants at December 31, 2017
1,437,435

Newly authorized shares

Granted
(360,999
)
Cancellation and forfeitures

Plan termination
(1,076,436
)
Available for future grants at June 30, 2018

Summary of SARs Outstanding
A summary of the Company’s SARs outstanding under the 2015 Plan are as follows:
 
Six Months Ended
 
June 30, 2018
SARs
Shares
 
Weighted-
Average
Exercise 
Price
Outstanding at beginning of year
1,817,991

 
$
65.73

Granted
87,310

 
149.57

Exercised
(384,528
)
 
58.18

Forfeited
(35,417
)
 
79.69

Expired
(438
)
 
108.20

Outstanding at end of period
1,484,918

 
$
72.28

Exercisable at end of period
797,045

 
$
58.20

Weighted-Average Assumptions Used for Grants of Stock Options and SARs
The following table shows the weighted-average assumptions used for grants of SARs, as well as the fair value of the grants based on those assumptions:
 
June 30, 2018
 
July 1, 2017
Expected dividend yield
0%
 
0%
Forfeiture rate
8.40%
 
9.37%
Volatility
35.93%
 
35.49%
Risk free interest rate
2.96%
 
1.77%
Range of interest rates
1.68% - 3.00%
 
0.71% - 2.41%
Expected weighted-average life (in years)
4.11
 
4.13
Fair value of SARs granted (in millions)
$13
 
$12
Weighted-average grant date fair value of SARs granted
(per underlying share)
$47.59
 
$29.84
Schedule of Outstanding and Exercisable Options
The following table summarizes information about non-qualified stock options outstanding at June 30, 2018:
 
Outstanding             
 
Exercisable         
Aggregate intrinsic value (in millions)
$
1

 
$
1

Weighted-average remaining contractual term (in years)
0.42

 
0.42

The following table summarizes information about SARs outstanding at June 30, 2018:
 
Outstanding
 
Exercisable         
Aggregate intrinsic value (in millions)
$
106

 
$
68

Weighted-average remaining contractual term (in years)
5.86

 
5.01

Summary of Restricted Stock Award Activity
A summary of information relative to the Company’s restricted stock awards is as follows:
 
 
Six Months Ended
 
 
June 30, 2018
Restricted Stock Awards
 
Shares
 
Weighted-Average
Grant Date Fair Value
Outstanding at beginning of year
 
628,642

 
$
77.70

Granted
 
199,025

 
149.41

Released
 
(144,957
)
 
109.21

Forfeited
 
(16,494
)
 
83.89

Outstanding at end of period
 
666,216

 
$
92.26

Summary of Performance Share Award Activity
The fair value of each performance award granted includes assumptions around the Company’s performance goals. A summary of information relative to the Company’s performance awards is as follows:
 
 
Six Months Ended
 
 
June 30, 2018
Performance Share Awards
 
Shares
 
Weighted-Average
Grant Date Fair Value
Outstanding at beginning of year
 
265,747

 
$
77.04

Granted
 
59,383

 
146.64

Released
 
(57,074
)
 
107.31

Forfeited
 
(6,518
)
 
80.17

Outstanding at end of period
 
261,538

 
$
86.24

Schedule of Share-based Compensation, Stock Options, Activity
A summary of the Company’s options outstanding under the 2006 Plan is as follows:
 
 
Six Months Ended
 
 
June 30, 2018
Non-qualified Options
 
Shares
 
Weighted-
Average
Exercise Price
Outstanding at beginning of year
 
15,705

 
$
26.34

Exercised
 
(9,083
)
 
31.26

Expired
 

 

Outstanding at end of period
 
6,622

 
$
19.59

Exercisable at end of period
 
6,622

 
$
19.59